PROF. DAVID RON, M.D.
Osteopathic Medicine at 1 Ave, New York, NY

License number

New York 190927-1

Personal information

See more information about DAVID RON at radaris.com

Name

Address

Phone

David Ron, age 68

1 Washington Square Vlg APT 6D, New York, NY 10012

David Ron

50 Guion Pl, New Rochelle, NY 10801

David Ron

1 Washington Square Vlg, New York, NY 10012

(212) 982-5991

David Ron, age 55

15218 Union Tpke, Flushing, NY 11367

(718) 380-0044

David Ron

New York, NY

(212) 982-5991

Organization information

See more information about DAVID RON at bizstanding.com

David Ron MD

540 1 Ave, New York, NY 10016

Industry:

Internist

Phone:

(212) 263-7300 (Phone)

David Ron

Professional information

See more information about DAVID RON at trustoria.com

David Ron, New York NY

Specialties:

Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism

Work:

New York University
540 1St Ave, New York, NY 10016

Education:

Technion Israel Institute Of Technology (1980)

Dr. David Ron, New York NY - MD (Doctor of Medicine)

Specialties:

Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism

Address:

540 1St Ave, New York 10016
(212) 263-7786 (Phone), (212) 263-8951 (Fax)

Certifications:

Diabetes, Metabolism & Endocrinology, 1989, Internal Medicine, 1987

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Technion-Israel Institute of Technology / Faculty of Medicine
Mount Sinai Hospital
Massachusetts General Hospital

Restaurants Professional

Location:

Greater New York City Area

Industry:

Restaurants

Method Of Identifying Substances Useful For Promoting Resistance To Cell Stress

US Patent:

7306905, Dec 11, 2007

Filed:

May 17, 2002

Appl. No.:

10/150759

Inventors:

David Ron - New York NY, US
Heather P. Harding - Brooklyn NY, US

Assignee:

New York University - New York NY

International Classification:

C12Q 1/68, C12Q 1/00

US Classification:

435 6, 435 4, 435 29

Abstract:

The invention is directed to methods for identifying test substances useful for the prevention or treatment of diseases involving an oxidative stress. The methods involve screening assays, including high throughput screening techniques, in which the test substances are tested for their ability to promote resistance to oxidative stress by activating one or more points of the integrated stress response pathway, while not causing stress.

Method Of Screening Test Substances For Treating Or Preventing A Disease Mediated By Plasma Cells

US Patent:

7666587, Feb 23, 2010

Filed:

Apr 11, 2003

Appl. No.:

10/413538

Inventors:

David Ron - New York NY, US
Marcella Calfon - New York NY, US
Heather Harding - Brooklyn NY, US
Yuhong Zhang - Elmhurst NY, US

Assignee:

New York University - New York NY

International Classification:

C12Q 1/68

US Classification:

435 6, 435 4

Abstract:

The present invention relates to a method of screening a compound for potential effectiveness in treating or preventing a mammalian disease mediated by plasma cells or a mammalian disease caused by virus infection of mammalian cells. Compounds are tested for their ability to inhibit IRE1-mediated processing of untranslatable XBP-1 mRNA into translatable XBP-1 mRNA. Drugs that are useful in treating or preventing a mammalian disease mediated by plasma cells and a method for detecting XBP-1 activity in living cells are also described.

Methods Of Screening Test Compounds Using Gadd34L, An Eif2Alpha-Specific Phosphatase Subunit

US Patent:

2004014, Jul 22, 2004

Filed:

Aug 28, 2003

Appl. No.:

10/650482

Inventors:

David Ron - New York NY, US
Celine Jousse - Saint Genes Champanelle, FR

International Classification:

C12Q001/68, G01N033/53, G01N033/567

US Classification:

435/006000, 435/007200

Abstract:

The invention is directed to methods and reagents for identifying test substances useful for the prevention or treatment of diseases involving an oxidative stress. The methods involve screening assays, including high throughput screening techniques, in which the test substances are tested for their ability to promote resistance to oxidative stress by inhibiting the activity of GADD34L, and thereby inhibiting the dephosphorylation of eIF2, while not causing stress.